newsfilter
← Latest News
GlobeNewswire·

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

  • Madrigal Pharmaceuticals granted equity inducement awards on June 15, 2026, to five new non-executive employees under its 2025 Inducement Plan.
  • The Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment acceptance.
  • The new employees received a total of 1,397 time-based restricted stock units that vest in four equal annual installments.
  • Vesting of the awards is contingent upon the employees maintaining continued employment on each applicable vesting date.
  • Madrigal focuses on treating MASH with Rezdiffra, the first FDA & EC-approved therapy for MASH with moderate to advanced fibrosis, while an ongoing Phase 3 trial evaluates its use for compensated MASH cirrhosis.